Notably, variant VκF94A + VHP97A, which had the lowest intrinsic EGFR affinity of ~150 nM (~250-fold less than parental DuetMab), induced the most significant tumor selectivity, while no substantial reduction in potency against the “target tumor” was observed. The gene discussed is EGFR; the disease is neoplasm.